Elevated expression of TIGIT and CD155 has been demonstrated in multiple human cancers, including melanoma [37], lung adenocarcinoma [38], hepatocellular carcinoma [39], pancreatic cancer [40], and gastric cancer [12], among other types of cancer, supporting the relevance of this immune axis as a therapeutic target in oncology. This evidence concerns the gene TIGIT and familial pancreatic carcinoma.